PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Some net income increase while AVXL is negative at -133.05%. John Neff would see a short-term edge over the struggling competitor.
-22.93%
Negative yoy D&A while AVXL is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
18.38%
Deferred tax of 18.38% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-40.28%
Negative yoy SBC while AVXL is 19.69%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
112.09%
Slight usage while AVXL is negative at -281.47%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
AP growth of 86.72% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
300.21%
Some yoy usage while AVXL is negative at -281.47%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-40.28%
Both negative yoy, with AVXL at -0.21%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
17.79%
Some CFO growth while AVXL is negative at -326.23%. John Neff would note a short-term liquidity lead over the competitor.
19.38%
CapEx growth of 19.38% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth of 99.99% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
98.29%
We expand invests by 98.29% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
684.38%
Stock issuance far above AVXL's 52.91%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.